This article looks at what a transition to propellants with lower Global Warming Potential will involve and the lessons that can be learned from the industry’s earlier transition from CFCs to HFAs. Key issues that need to be addressed as formulators learn to work with propellants such as HFA 152a and HFO 1234ze include solubility of the active, the profile of the emitted spray, droplet size and evaporation, and electrostatic characteristics.
Aptar Pharma offers a comprehensive suite of services for those looking to accelerate their transition to low carbon MDIs including the Nanopharm SmartTrack™ platform which provides a wealth of information for formulation optimization.
Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery
This Might Also Be of Interest
From pMDI Device to Therapeutic Effect
Webinars, Pharmaceutical, Sustainability, Device Innovations, Market Insights, Product Solutions
Physiologically-based Pharmacokinetic Models (PBPK) for OINDPs
Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions
Under Pressure: Finding a More Sustainable Future for pMDIs
Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions
Digital Health and Digital Therapeutics: Where are we heading and why?
Webinars, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions
